Quantum Genesis AI Corp. (OTC: QGAI) issued a statement on March 12, 2026, regarding the Caveat Emptor designation placed on its securities by OTC Markets Group, Inc. on February 12, 2026. The company, which focuses on artificial intelligence, computational modeling, and scientific innovation, has been working to understand the basis for the designation and determine necessary steps to address it.
OTC Markets indicated the designation relates to a “public interest concern.” Quantum Genesis AI has requested additional clarification and intends to continue cooperating with OTC Markets. The company was recently informed it may formally request a review of the designation beginning March 13, 2026, and plans to engage at the earliest opportunity.
“We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation,” said Naveen Kulkarni, Chief Executive Officer. “Our objective is to obtain clarity and take appropriate steps through the review process.”
The company remains committed to transparency with shareholders and the investment community. It will provide updates as more information becomes available. For more information, visit www.qgaicorp.com and the company’s profile at www.otcmarkets.com/stock/QGAI.
Quantum Genesis AI Corp. focuses on advancing next-generation technologies at the intersection of AI, computational modeling, and scientific innovation. Its strategy includes leveraging data-driven tools to support research and development across emerging sectors while maintaining transparency and responsible governance.
Forward-looking statements in the press release involve risks and uncertainties that could cause actual results to differ materially. The company undertakes no obligation to update forward-looking statements except as required by law. This information is for general purposes only and does not constitute an offer to sell or solicitation of an offer to buy securities.
